Listing Websites about Acadia Pharmaceuticals
(9 days ago) Acadia is trailblazing breakthroughs in neuroscience to elevate life. We are at the forefront of healthcare, fighting for breakthroughs in our science, our therapies and the way we work, but also in the lives of the people we serve. At Acadia, we are committed to our purpose: we …
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News
(6 days ago) ACADIA Pharmaceuticals (NASDAQ:ACAD shareholders incur further losses as stock declines 5.1% this week, taking one-year losses to 56%. Investing in stocks comes with the risk that the share price
ACAD Stock Forecast, Price & News (ACADIA Pharmaceuticals)
(6 days ago) ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACAD stock has decreased by 52.9% and is now trading at $17.38. View which stocks have been most impacted by COVID-19.
Leandra Gargiulo - Regional Sales Manager - Byram
(3 days ago) Amylin Pharmaceuticals - a wholly owned subsidiary of Bristol-Myers Squibb Apr 2005 - Jun 2009 4 years 3 months. Northeast Business manager Regional Sales Manager at ACADIA Pharmaceuticals …
Acadia Pharmaceuticals Inc. (ACAD) Stock Message Board
(9 days ago) ACAD News: Acadia Pharmaceuticals to Present at Upcoming Investor Conferences. 09/02/2021 05:00:00 AM. ACAD News: Acadia Pharmaceuticals Announces Executive Leadership Change. 09/01/2021 12:05:00 PM. ACAD News: Dermata therapeutics appoints Kyri Van Hoose as CFO.
ACADIA Pharmaceuticals Company Profile - Office Locations
(9 days ago) ACADIA Pharmaceuticals (formerly known as Receptor Technologies) is a biopharmaceutical company focused on the development and commercialization of medicines that address medical needs in central nervous system (CNS) disorders. Its main product is NUPLAZID that is used for the treatment of hallucinations and delusions associated with Parkinson
Investors Acadia Pharmaceuticals Inc.
(8 days ago) Acadia Pharmaceuticals Announces Executive Leadership Change. SAN DIEGO -- (BUSINESS WIRE)--Sep. 1, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Elena Ridloff , Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceutical company.
Parkinson's-Related Hallucinations & Delusions Treatment
(5 days ago) You can also call Acadia Pharmaceuticals Inc. at 1‑844‑4ACADIA (1‑844‑422‑2342). Indication NUPLAZID is a prescription medicine used to treat hallucinations and delusions associated with Parkinson’s disease psychosis.
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price Today
(6 days ago) ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
Working at ACADIA Pharmaceuticals: Employee Reviews
(7 days ago) ACADIA Pharmaceuticals insights. Based on 10 survey responses. What people like. General feeling of work happiness. Supportive environment. Time and location flexibility. Areas for improvement. Ability to meet personal goals. Support from manager.
ACADIA Pharmaceuticals Inc. (ACAD) Latest Stock News
(2 days ago) ACADIA Pharmaceuticals Inc. Analyst Report: Pfizer Inc. Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on
Acadia Pharmaceuticals - Wikipedia
(2 days ago) Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California. Product development. Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning."
Acadia Pharma Dives On Unexpected Flop In Depression Treatment
(9 days ago) Acadia Pharmaceuticals said Tuesday its experimental depression treatment failed in a Phase 3 study — prompting ACAD stock to plunge.. X. Researchers tested the drug, dubbed Nuplazid, in
5 Top Biotech Stocks to Buy for 2021 With Massive Upside
(Just Now) Acadia Pharmaceuticals. This stock helped to drive the strong outperformance from the firm’s top picks list for November. Acadia Pharmaceuticals Inc. ( NASDAQ: ACAD) is focused on the
ACADIA Pharmaceuticals Stock Competitors - MarketBeat
(5 days ago) ACADIA Pharmaceuticals (NASDAQ:ACAD) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior business?We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and …
About NUPLAZID® (pimavanserin) - Indication, Dosing
(9 days ago) You can also call Acadia Pharmaceuticals Inc. at 1‑844‑4ACADIA (1‑844‑422‑2342). Indication NUPLAZID is a prescription medicine used to treat hallucinations and delusions associated with Parkinson’s disease psychosis.
ACADIA Pharmaceuticals - AnnualReports.com
(Just Now) ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.
ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on
(4 days ago) ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD) Q2 2021 Earnings Conference Call August 4, 2021 04:30 PM ET Company Participants Mark Johnson - VP, IR Stephen Davis - Chief Executive Officer
Should You Buy ACADIA Pharmaceuticals Stock At $22?
(8 days ago) We believe that ACADIA Pharmaceuticals stock (NASDAQ NDAQ -0.3%: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock
Acadia Pharmaceuticals Receives Complete Response Letter
(5 days ago) Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with
ACADIA Pharmaceuticals Inc Stock Forecast up to $27.86
(9 days ago) ACADIA Pharmaceuticals Inc Stock Forecast. Over the next 52 weeks, ACADIA Pharmaceuticals Inc has on average historically risen by 65.9 % based on the past 17 years of stock performance. ACADIA Pharmaceuticals Inc has risen higher in 9 of those 17 years over the subsequent 52 week period, corresponding to a historical accuracy of 52.94 %
NUPLAZID® (pimavanserin) For Healthcare Professionals
(8 days ago) Acadia Pharmaceuticals Inc. NUPLAZID ® [package insert]. San Diego, CA; 2020. US Food and Drug Administration. FDA approves first drug to treat hallucinations and delusions associated with …
ACAD: ACADIA Pharmaceuticals Inc - Stock Price, Quote and
(2 days ago) ACADIA Pharmaceuticals Inc. (ACADIA) is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines to address the medical needs in central nervous
ACAD - Stock quote for ACADIA PHARMACEUTICALS INC. - MSN …
(4 days ago) Acadia Pharmaceuticals Inc (ACAD): Price Now Near $18.09; Daily Chart Shows An Uptrend on 20 Day Basis ETF Daily News 8 hrs ago For ACADIA Pharmaceuticals Inc. [ACAD], Analyst sees a rise to $20.
Acadia Pharmaceuticals Jobs Glassdoor
(9 days ago) Acadia Healthcare Jobs. 2.7 ★ ( 466 Reviews) Acadia Pharmaceuticals. Save Job. Director/Senior Director Preclinical Sciences. San Diego, CA 29d. Acadia Pharmaceuticals. Save Job. Senior Director Clinical Operations.
ACAD Stock Forecast, Price Targets and Analysts
(5 days ago) Analyst Price Target on ACAD. Based on 13 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $27.33 with a high forecast of $35.00 and a low forecast of $18.00. The average price target represents a 61.05% change from the last price of $16.97.
Acadia, with drug application rejected, calls out FDA for
(Just Now) The Food and Drug Administration has turned down a request to approve pimavanserin, a medicine from Acadia Pharmaceuticals, for patients with dementia-related psychosis. Acadia said the rejection was tied to issues with the main study used in its approval application. Investors have been bracing for a rejection since last month, when Acadia
Acadia Pharmaceuticals Announces Executive Leadership
(7 days ago) Media Contact: Acadia Pharmaceuticals Inc. Eric Endicott (858) 914-7161 [email protected]acadia-pharm.com Investor Contact: Acadia Pharmaceuticals Inc. Mark Johnson, CFA (858) 261-2771 [email protected]acadia-pharm.com
ACAD ACADIA Pharmaceuticals Inc. Profile MarketWatch
(4 days ago) ACADIA Pharmaceuticals Inc. 12830 El Camino Real. Suite 400. San Diego, California 92130-3331. Phone 1 858 558-2871. Industry Biotechnology. Sector Health Care/Life Sciences.
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, Quote
(8 days ago) Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021. SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021, at 3:00 p
Acadia Pharmaceuticals Inc. - Funding, Financials
(1 days ago) Acadia Pharmaceuticals Inc. has raised a total of $811.7M in funding over 14 rounds. Their latest funding was raised on Sep 20, 2019 from a Post-IPO Equity round. Acadia Pharmaceuticals Inc. is registered under the ticker NASDAQ:ACAD . Their stock opened with $7.00 in its May 27, 2004 IPO. Acadia Pharmaceuticals Inc. is funded by 17 investors.
ACADIA Pharmaceuticals Careers and Employment Indeed.com
(9 days ago) Find out what works well at ACADIA Pharmaceuticals from the people who know best. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Compare pay for popular roles and read about the team’s work-life balance. Uncover why ACADIA Pharmaceuticals is the best company for you.
Jobs with Acadia Pharmaceuticals - BioSpace
(4 days ago) Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2020. Acadia Pharmaceuticals to Present at Upcoming Investor Conferences - Feb 18, 2021. 2/18/2021. Acadia Pharmaceuticals Inc. announced that it will participate at the following investor conferences
Acadia Pharmaceuticals Inc. in Charleston, WV Company
(Just Now) Acadia Pharmaceuticals Inc. is a West Virginia Foreign Profit Corporation filed On September 2, 2016. The company's filing status is listed as Active and its File Number is 358607. The Registered Agent on file for this company is Corporation Service Company and is located at 209 West Washington Street, Charleston, WV 25302.
FAQ about Acadia Pharmaceuticals
What kind of company is Acadia Pharmaceuticals Corporation?
ACADIA Pharmaceuticals (formerly known as Receptor Technologies) is a biopharmaceutical company focused on the development and commercialization of medicines that address medical needs in central nervous system (CNS) disorders.
What are the price targets for Acadia Pharmaceuticals?
Based on 11 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $30.30 with a high forecast of $62.00 and a low forecast of $18.00. The average price target represents a 27.63% change from the last price of $23.74.
When does Acadia Pharmaceuticals plan to file for sNDA?
The company plans to submit a supplemental New Drug Application (sNDA) in the summer, and expects a priority review (expedited via the breakthrough therapy designation) and a potential approval near the end of the year. Management took proactive steps to adapt to the dynamic environment created by the COVID-19 pandemic.
What are the valuation metrics for Acadia Pharmaceuticals?
Another important valuation metric is enterprise value to sales (EV/Sales), which compares the company's overall enterprise value to its sales; Acadia's EV/Sales of 20.1 shows it to be overvalued compared with Clovis Oncology (6.6) and Intercept Pharmaceuticals (9.8).